Allucent Patient Direct Trials will provide small and mid-sized biotech companies with access to advanced technologies. Credit: National Cancer Institute on Unsplash.

Allucent has partnered with eCOA technology provider Thread to launch Allucent Patient Direct Trials, a decentralised clinical trial (DCT) offering that is focused on small and mid-sized biotech firms.

The launch will provide these companies with access to the latest technologies, regulatory expertise, and operational experience.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Allucent improved its patient-centric approaches and guidance for optimising clinical protocols after the Covid-19 pandemic.

Leveraging this experience, the offering will address the needs of the biotech companies in designing and overseeing customised DCT approaches.

The partnership will also help Allucent’s regulatory and product development consultant team to guide sponsors in determining effective digital strategies for remote engagement and data collection for their studies.

See Also:

Allucent chairman and CEO Mark Goldberg said: “With this launch, we’re helping our clients harness new insights and technologies to be more patient-centric and realise the potential and efficiencies of decentralised approaches to clinical research.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

DCTs can make patient participation more accessible and manageable.

They can also accelerate enrolment, help retain subjects, and increase the overall participant pool diversity to make the trial results more representative for real-world effectiveness.

In March this year, United BioSource and Threadlaunched the next-generation, post-approval research model, SitePlus.

The new research model provides nationwide, direct-to-patient recruitment strategies and enables inclusive, diverse patient population enrolment.